Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). Population-based reference values in an area with low incidence of cardiovascular disease

Clinical Biochemistry

Volumn 36, Issue 2, 2003, Pages 129-134

  Simó, Josep M ^a   Camps, Jordi ^a   Gómez, Frederic ^a   Ferré, Natàlia ^a   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Atherosclerosis; Cardiovascular risk factor; Immunoturbidimetric analysis; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN B; LIPOPROTEIN A; PLASMINOGEN; REAGENT;

ACCURACY; ADULT; AGED; ARTICLE; AUTOMATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIAGNOSTIC KIT; EVALUATION; FEMALE; HEMOLYSIS; HUMAN; HYPERLIPIDEMIA; IMMUNOASSAY; JAUNDICE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORBIDITY; PARAPROTEINEMIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN POLYMORPHISM; SEASHORE; SPAIN; TURBIDIMETRY;

EID: 0037334742     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(02)00416-2     Document Type: Article

References (37)

1. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand. 59:1963;369-381.
2. Berg K., Dahlen G., Frick M. Lp(a) lipoprotein, and pre-β-lipoproteins in patients with coronary heart disease. Clin Genet. 6:1974;230-235.
3. Kostner G.M., Avogaro P., Cazzolato G., Marth E., Bittolo B.G., Quinci G.B. Lipoprotein Lp(a), and the risk for myocardial infartion. Atherosclerosis. 38:1981;51-61.
4. Scanu A.M. Lipoprotein(a) a potential bridge between the fields of atherosclerosis, and thrombosis . Arch Pathol Lab Med. 112:1988;1045-1047.
5. Sigurdsson G., Baldursdottir A., Sigvaldason H., Agnarsson U., Thorgeisson G., Sigfusson N. Predictive value of apolipoproteins in prospective survey of coronary artery disease in men. Am J Cardiol. 69:1992;1251-1254.
6. Martín S., Pedro-Botet J., Joven J., et al. Heterozygous apolipoprotein(a) status and protein expression as a risk factor for premature coronary heart disease. J Lab Clin Med. 139:2001;181-187.
7. Lundstam U., Herlitz J., Karlsson T., Lindén T., Wiklund O. Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med. 25:2002;111-118.
8. Gaubatz J.W., Heideman C., Gotto A.M., Morrisett J.D., Dahlen G.H. Human plasma lipoprotein(a). Structural properties. J Biol Chem. 258:1983;4582-4589.
9. Fless G.M., ZumMallen M.E., Scanu A.M. Isolation of apolipoprotein(a) from lipoprotein(a). J Lipid Res. 26:1985;1224-1229.
10. Seman L.J., Breckinridge W.C. Isolation and partial characterization of apolipoprotein(a) from human lipoprotein(a). Biochem Cell Biol. 64:1986;999-1009.
11. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C.H. Lp(a) glycoprotein phenotypes inheritance, and relation to the Lp(a)-Lipoprotein concentration in plasma. J Clin Invest. 80:1987;458-467.
12. Fless G.M., Rolih C.A., Scanu A.M. Heterogeneity of human plasma lipoprotein(a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem. 259:1984;11470-11478.
13. Ehnholm C., Garoff H., Simons K., Aro H. Purification and quantification of the human plasma carrying the Lp(a) antigen. Biochem Biophys Acta. 236:1971;430-439.
14. Gaubatz J.W., Chari M.V., Nava M.L., Guyton J.R., Morrissett J.D. Isolation and characterization of the two major apoproteins in human lipoprotein(a). J Lipid Res. 28:1987;69-79.
15. Fless G.M., ZumMallen M.E., Scanu A.M. Physiochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem. 261:1986;8712-8718.
16. McLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
17. Castellino F.J., Beals J.M. The genetic relatioships between the kringle domains of human plasminogen prothrombin tissue plasminogen activator urokinase and coagulation factor XII. J Mol Evol. 26:1987;358-369.
18. Guevara J., Knapp R.D., Honda S., Northup S.R., Morrisett J.D. A structural assessment of the apo(a) protein of human lipoprotein(a). Proteins. 12:1992;188-189.
19. Marcovina S.M., Albers J.J., Gabel B., Koschinsky M.L., Gaur V.P. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clinical Chemistry. 41:1995;246-255.
20. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H.J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 9:1989;579-592.
21. Cushings G.L., Gaubatz J.W., Nava M.L., et al. Quantification and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 9:1989;593-603.
22. Pepin J.M., O'Neil J.A., Hoff H.F. Quantification of apo(a) and apo B in human atherosclerotic lesions. J Lipid Res. 32:1991;317-326.
23. Vu-Dac N., Chekkor A., Parra H., Duthileul P., Fruchart J.C. Latex immunoassay of human serum Lp(a) lipoprotein. J Lipid Res. 26:1985;267-269.
24. Marcovina S.M. Lippi G, Guidi G. Lipoprotein(a) immunoassays comparison of a semi-quantitative latex method, and two monoclonal enzyme immunoassays . Int J Clin Lab Res. 25:1995;201-204.
25. Levine D.M., Sloan B.J., Donner J.E., Lorenz J.D., Heinzerling R.H. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res. 22:1992;173-178.
26. Tate J.R., Rifai N., Berg K., et al. International Federation of Clinical Chemistry Standardization Project for the Measurement of Lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and calibrators. Clin Chem. 44:1998;1629-1640.
27. Tate J.R., Berg K., Couderc R., et al. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Standardization Project for the Measurement of Lipoprotein(a). Phase 2. Selection and Properties of a proposed secondary reference meterial for lipoprotein(a). Clin Chem Lab Med. 37:1999;949-958.
28. Marcovina S.M., Albers J.J., Scanu A.M., et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem. 46:2000;1956-1967.
29. Fortmann S.P., Marcovina S.M. Lipoprotein(a), a clinically elusive lipoprotein particle. Circulation. 95:1997;295-296.
30. Tunstall H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Circulation. 90:1994;583-612.
31. Simó J.M., Joven J., Vilella E., et al. Impact of apolipoprotein(a) isoform size heterogeneity on the lysine binding function of lipoprotein(a) in early onset coronary artery disease. Thromb Haemost. 85:2001;412-417.
32. Simó J.M., Joven J., Vilella E., et al. Polymorphisms in human apolipoprotein(a) kringle IV-10 and coronary artery disease relationship to allele size, plasma apolipoprotein(a) concentration, and lysine binding site activity . J Mol Med. 79:2001;294-299.
33. Simó J.M., Joven J., Clivillé X., Sans T. Automated latex agglutination immunoassay of serum ferritin with a centrifugal analyzer. Clin Chem. 40:1994;625-629.
34. Yamada S., Inoue K., Morishita R., et al. A new Lp(a) assay that is unaffected by apo(a) size polymorphism. Clin Chim Acta. 287:1999;29-43.
35. Dembinski T., Nixon P., Shen G., Mymin D., Choy P.C. Evaluation of a new apolipoprotein(a) isoform-independent assay for serum Lipoprotein(a). Mol Cell Biochem. 207:2000;149-155.
36. Marcovina S., Albers J.J., Wijsman E., Zhang Z.H., Chapman N.H., Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J Lip Res. 37:1996;2569-2585.
37. Henriksson P., Angelin B., Berglund L. Hormonal regulation of serum Lp(a) levels Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma . J Clin Invest. 89:1992;1166-1171.